Trial Profile
The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam, a Cytochrome P450 3A4/P-gp (CYP3A4) Substrate, in Postmenopausal Osteoporotic Women.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Midazolam
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Amgen
- 01 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.